SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells. AML is challenging to treat in older patients since intensive chemotherapy is poorly tolerated, and standard therapies, such as the hypomethylating agents (HMAs) azacitidine and decitabine, yield modest response rates. Data are presented from an ongoing phase 1 trial evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with standard therapies (azacitidine, decitabine) in older AML patients who have declined intensive frontline therapy. 33A is an antibody-drug conjugate (ADC) targeted to CD33, comprising a novel antibody system stably linked to a highly potent cell-killing agent. CD33 is expressed on leukemic blasts in nearly all AML patients and expression is generally consistent regardless of age, risk factors, or disease characteristics.

Thus far, 53 AML patients with median age of 75 years have been treated with this combination. Of 49 efficacy-evaluable patients treated with 33A combined with either azacitidine or decitabine, the composite complete remission rate (CR+CRi) was 73 percent, which compares favorably with historical studies of HMA monotherapy in this population. The 30- and 60-day mortality rates were two and eight percent, respectively. The most common Grade 3 or higher treatment-emergent adverse events occurring in 20 percent or more of patients were febrile neutropenia, thrombocytopenia, anemia and neutropenia. The combination of 33A and HMAs was well-tolerated and yielded encouraging response rates in older AML patients.

Presenter: Dr Amir Fathi

Affiliation: Massachusetts General Hospital Cancer Center, Boston, USA

Topic: SGN-CD33A IN COMBINATION WITH HYPOMETHYLATING AGENTS: A NOVEL, WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN OLDER PATIENTS WITH AML

Abstract S503 will be presented by Amir Fathi on Saturday, June 11, 16:30 - 16:45 in Hall A3.

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments. The latest data on research and developments will be presented. The topics range from stem cell physiology and development, to leukemia, lymphoma, myeloma - diagnosis and treatment; red blood cells -, white blood cells- and platelet disorders; thrombosis and bleeding disorders.

Contact

EHA Executive Office

Ineke van der Beek, Jon Tarifa

E-mail: communication@ehaweb.org

Mobile: +31(0)6 2011 1055

 

Last Updated on Tuesday 05 June 2018.